PMID- 11229514
OWN - NLM
STAT- MEDLINE
DCOM- 20010322
LR  - 20191210
IS  - 1525-1578 (Print)
IS  - 1525-1578 (Linking)
VI  - 2
IP  - 3
DP  - 2000 Aug
TI  - The development of a multitarget, multicolor fluorescence in situ hybridization 
      assay for the detection of urothelial carcinoma in urine.
PG  - 116-23
AB  - The purpose of this study was to develop a multitarget, multicolor fluorescence 
      in situ hybridization (FISH) assay for the detection of urothelial carcinoma (UC) 
      in urine specimens. Urinary cells obtained from voided urine specimens of 21 
      patients with UC and 9 normal donors were analyzed with nine different centromere 
      enumeration probes and a single locus-specific indicator probe to determine an 
      optimal set of FISH probes for UC detection. The four probes with the greatest 
      sensitivity for UC detection were then labeled with a unique fluorophore and 
      combined into a single probe set. The probes with the greatest combined 
      sensitivity for UC detection were CEP3, CEP7, CEP17, and the 9p21 (P16) LSI. This 
      probe set was used to evaluate urine specimens acquired from 179 patients for 
      prospective testing (46 with biopsy-proven UC). FISH slides were evaluated by 
      scanning the slide for cells with nuclear features suggestive of malignancy and 
      assessing the FISH signal pattern of these cells for polysomy (ie, gains of two 
      or more different chromosomes). A receiver operator characteristic curve revealed 
      that a cutoff of 5 cells with polysomy as the positive criterion for cancer 
      resulted in an overall sensitivity of 84.2% for patients with biopsy-proven UC 
      and a specificity of 91.8% among patients with genitourinary disorders but no 
      evidence of UC. This study demonstrates that a multitarget, multicolor FISH assay 
      containing centromeric probes to chromosomes 3, 7, and 17 and a locus-specific 
      probe to band 9p21 has high sensitivity and specificity for the detection of UC 
      in voided urine specimens.
FAU - Sokolova, I A
AU  - Sokolova IA
AD  - Vysis, Inc., Downers Grove, Illinois 60515, USA.
FAU - Halling, K C
AU  - Halling KC
FAU - Jenkins, R B
AU  - Jenkins RB
FAU - Burkhardt, H M
AU  - Burkhardt HM
FAU - Meyer, R G
AU  - Meyer RG
FAU - Seelig, S A
AU  - Seelig SA
FAU - King, W
AU  - King W
LA  - eng
PT  - Clinical Trial
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Mol Diagn
JT  - The Journal of molecular diagnostics : JMD
JID - 100893612
RN  - 0 (DNA Probes)
SB  - IM
MH  - Aneuploidy
MH  - Centromere/genetics
MH  - Chromosome Banding
MH  - Chromosomes, Human/genetics
MH  - Color
MH  - DNA Probes/genetics
MH  - Epithelial Cells/metabolism/pathology
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Microscopy, Fluorescence
MH  - Reference Values
MH  - Sensitivity and Specificity
MH  - Urinary Bladder Neoplasms/diagnosis/genetics/pathology/urine
MH  - Urogenital Neoplasms/*diagnosis/genetics/pathology/*urine
PMC - PMC1906906
EDAT- 2001/03/07 10:00
MHDA- 2001/03/27 10:01
PMCR- 2001/08/01
CRDT- 2001/03/07 10:00
PHST- 2001/03/07 10:00 [pubmed]
PHST- 2001/03/27 10:01 [medline]
PHST- 2001/03/07 10:00 [entrez]
PHST- 2001/08/01 00:00 [pmc-release]
AID - S1525-1578(10)60625-3 [pii]
AID - 0031 [pii]
AID - 10.1016/S1525-1578(10)60625-3 [doi]
PST - ppublish
SO  - J Mol Diagn. 2000 Aug;2(3):116-23. doi: 10.1016/S1525-1578(10)60625-3.